灯盏生脉胶囊治疗慢性心力衰竭的疗效与安全性：一项系统评价与Meta分析
Efficacy and safety of Dengzhan Shengmai capsule in the treatment of chronic heart failure: a systematic review and meta-analysis.
作者信息
Lu Shenghua, Yu Yunfeng, Dai Sisi, Hu Yaqi, He Qin, Liu Rongzhen, Liu Jianhe
机构信息
Department of Cardiovascular Medicine, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Branch of National Clinical Research Center for Chinese Medicine Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
出版信息
Front Cardiovasc Med. 2025 Feb 21;12:1385061. doi: 10.3389/fcvm.2025.1385061. eCollection 2025.
BACKGROUND
Dengzhan Shengmai Capsule (DZSMC) is a potential treatment for chronic heart failure (CHF). However, its specific benefits in the treatment of CHF remain unclear.
METHODS
Related randomized controlled trials were searched in eight databases up to January 28, 2025, and included studies were determined according to the inclusion criteria. Subsequently, the basic characteristics and data from these studies were recorded using Excel 2010. Outcome-related data were subsequently imported into Revman 5.3 for meta-analysis.
RESULTS
Fifteen randomized controlled trials with 1606 patients were included in this meta-analysis. The results showed that compared to conventional treatment group, DZSMC combination group significantly improved the clinical effective rate [RR = 1.21, 95% CI (1.16,1.26), < 0.00001], brain natriuretic peptide (BNP) [MD = -112.60, 95%CI (-212.23, -12.96), = 0.03], N-terminal pro-B-type natriuretic peptide (NT-proBNP) [MD = -88.27, 95%CI (-108.11, -68.42), < 0.00001], left ventricular ejection fraction (LVEF) [MD = 6.42, 95% CI (5.57, 7.27), < 0.00001], left ventricular end-diastolic diameter (LVEDD) [MD = -5.72, 95% CI (-7.56, -3.87), < 0.00001], left ventricular end-systolic diameter (LVESD) [MD = -5.33, 95% CI (-7.41, -3.26), < 0.00001], left ventricular end-systolic volume (LVESV) [MD = -20.71, 95% CI (-34.59, -6.82), = 0.003], and 6 min walk test [MD = 51.90, 95%CI (19.08, 84.72), = 0.002], while adverse events had no significant difference [RR = 0.70, 95%CI (0.42, 1.17), = 0.17]. Funnel plots indicated no publication bias for BNP, NT-proBNP, LVEF, and LVESD, while potential bias was observed for other outcomes.
CONCLUSION
DZSMC effectively improves clinical symptoms, cardiac function, and ventricular remodeling in CHF patients, with good safety, making it a potential adjuvant therapy for CHF. However, further research is needed to explore the long-term safety of DZSMC in order to enrich clinical evidence.
SYSTEMATIC REVIEW REGISTRATION
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507368, PROSPERO [CRD42024507368].
背景
灯盏生脉胶囊（DZSMC）是慢性心力衰竭（CHF）的一种潜在治疗方法。然而，其在CHF治疗中的具体益处仍不明确。
方法
截至2025年1月28日，在八个数据库中检索相关随机对照试验，并根据纳入标准确定纳入研究。随后，使用Excel 2010记录这些研究的基本特征和数据。随后将与结局相关的数据导入Revman 5.3进行荟萃分析。
结果
本荟萃分析纳入了15项随机对照试验，共1606例患者。结果显示，与常规治疗组相比，DZSMC联合治疗组显著提高了临床有效率[RR = 1.21，95%CI（1.16，1.26），P < 0.00001]、脑钠肽（BNP）[MD = -112.60，95%CI（-212.23，-12.96），P = 0.03]、N末端B型利钠肽原（NT-proBNP）[MD = -88.27，95%CI（-108.11，-68.42），P < 0.00001]、左心室射血分数（LVEF）[MD = 6.42，95%CI（5.57，7.27），P < 0.00001]、左心室舒张末期内径（LVEDD）[MD = -5.72，95%CI（-7.56，-3.87），P < 0.00001]、左心室收缩末期内径（LVESD）[MD = -5.33，95%CI（-7.41，-3.26），P < 0.00001]、左心室收缩末期容积（LVESV）[MD = -20.71，95%CI（-34.59，-6.82），P = 0.003]和6分钟步行试验[MD = 51.90，95%CI（19.08，84.72），P = 0.002]，而不良事件无显著差异[RR = 0.70，95%CI（0.42，1.17），P = 0.17]。漏斗图显示BNP、NT-proBNP、LVEF和LVESD无发表偏倚，而其他结局观察到潜在偏倚。
结论
DZSMC有效改善CHF患者的临床症状、心脏功能和心室重构，安全性良好，使其成为CHF的一种潜在辅助治疗方法。然而，需要进一步研究以探索DZSMC的长期安全性，以丰富临床证据。
系统评价注册
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024507368，PROSPERO [CRD42024507368]
Zotero 插件